SARS-CoV-2及相关冠状病毒化学感觉与鼻窦功能障碍的汇总患病率
本研究通过检索PubMed/MEDLINE数据库,汇总分析描述COVID-19、SARS-CoV-2、SARS-CoV-1、MERS-CoV及其他冠状病毒感染中嗅觉、味觉或鼻窦功能障碍的文献。汇总分析显示,SARS-CoV-2感染者嗅觉丧失发生率为49.6%(95%CI 46.5%-52.7%),味觉丧失为47.9%(95%CI 44.8%-51.0%),嗅觉或味觉丧失为17.9%(95%CI 16.9%-19.0%);其他冠状病毒感染的流涕/鼻溢/鼻炎和鼻塞/鼻梗阻/阻塞发生率显著高于SARS-CoV-2(P < .001)。
要点
- SARS-CoV-2感染者嗅觉丧失汇总发生率为49.6%,味觉丧失为47.9%。
- 嗅觉或味觉丧失的汇总发生率为17.9%。
- 其他冠状病毒的流涕和鼻塞发生率显著高于SARS-CoV-2(P < .001)。
核心结论
- SARS-CoV-2感染者中嗅觉和味觉丧失的汇总发生率较高,而其他冠状病毒感染的鼻部症状发生率显著更高。
研究设计与样本
- 研究利用美国国家医学图书馆PubMed/MEDLINE数据库检索描述COVID-19、SARS-CoV-2、SARS-CoV-1、MERS-CoV及其他冠状病毒并提及嗅觉、味觉或其他化学感觉或鼻窦功能障碍的文献,进行汇总分析。
主要发现
- SARS-CoV-2感染者嗅觉丧失发生率为49.6%(n=497/1002;95%CI 46.5%-52.7%)。
- SARS-CoV-2感染者味觉丧失发生率为47.9%(n=480/1002;95%CI 44.8%-51.0%)。
- SARS-CoV-2感染者嗅觉或味觉丧失发生率为17.9%(n=880/4909;95%CI 16.9%-19.0%)。
- 其他冠状病毒感染的流涕/鼻溢/鼻炎和鼻塞/鼻梗阻/阻塞发生率显著高于SARS-CoV-2(P < .001)。
临床怎么用
- 了解这些较少被充分描述的症状有助于开发评估疾病患病率早期标志物和/或恢复情况的措施。
局限性
- 证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Much of the published literature regarding the novel coronavirus disease 2019 (COVID-19) constitutes lower respiratory system symptomatology, while there exists a paucity of data describing the complicated sequelae of the upper respiratory system, including chemosensory and/or sinonasal dysfunction. This study utilized the National Library of Medicine's PubMed/MEDLINE database to query for articles describing COVID-19, SARS-CoV-2, SARS-CoV-1, MERS-CoV, and other coronaviruses, with any mention of smell, taste, or other chemosensory or sinonasal dysfunction. Aggregate analysis demonstrated an incidence of 49.6% (n = 497 of 1002; 95% CI, 46.5%-52.7%), 47.9% (n = 480 of 1002; 95% CI, 44.8%-51.0%), and 17.9% (n = 880 of 4909; 95% CI, 16.9%-19.0%) for smell loss, taste loss, and smell or taste loss, respectively, in patients infected with SARS-CoV-2. Additionally, there were significantly higher incidences of runny nose/rhinorrhea/rhinitis and nasal congestion/obstruction/blockage in other coronaviruses as compared with SARS-CoV-2 (P < .001). Understanding these less well-characterized symptoms may help develop measures for estimating early markers of disease prevalence and/or resolution. Level of evidence: 4.
引用
- Lehrich BM, Goshtasbi K, Raad RA, et al. Aggregate Prevalence of Chemosensory and Sinonasal Dysfunction in SARS-CoV-2 and Related Coronaviruses. Otolaryngol Head Neck Surg. 2020. PMID: 32423285. doi:10.1177/0194599820929278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。